Merck Talks to Acquire MoonLake for $3 Billion as Stock Surges; Owens & Minor-Rotech Deal Terminated

Merck & Co. engaged in discussions to acquire MoonLake Immunotherapeutics for over $3 billion as part of its strategy to bolster its drug development pipeline. The potential takeover has driven a surge in MoonLake's stock price, reflecting investor interest in the deal. Reports indicate that Merck's offer could revive attention in late-phase biotechnology companies. Meanwhile, MoonLake's potential sale has been interpreted by some analysts as a sign of distress for the biotech firm. In a separate development, Owens & Minor and Rotech Healthcare mutually agreed to terminate their previously announced acquisition agreement.